Symbols

NGNE

Neurogene·NASDAQ

--(--)

Signals Analysis

Bullish signal 3

Bearish signal 1

Stock Price Surged Significantly

Consensus Rating "Strong Buy"

Ample Liquidity

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About NGNE

Neurogene Inc.

A biopharmaceutical company using protein design technology to develop immunotherapies

Industry

Biological Technology

Established Date

Listing Date

03/07/2014

Exchange

NASDAQ Stock Exchange

Full-time Employees

131

Fiscal Year Ends

12-31

Website

www.neurogene.com

Security Type

Common stock

Office address

535 W 24th St., 5th Floor, New York, NY 10011

Business

Introduction

Neurogene Inc., originally incorporated in Delaware in May 2007 under the name Aquinox Pharmaceuticals, adopted its current name in December 2023 after a series of mergers and name changes. The company is a clinical-stage biotechnology company that leverages its proprietary EXACT transgenic regulation technology to focus on the development of genetic medicines for rare neurological diseases.

Company Financials

EPS

NGNE has released its 2025 Q4 earnings. EPS was reported at -1.12, versus the expected -1.24, beating expectations. The chart below visualizes how NGNE has performed over recent quarters, highlighting trends in earnings surprises.